The treatment landscape for advanced hepatocellular carcinoma has changed dramatically over the past 4 years. We now have numerous options for patients in frontline, second-line, and beyond. The most ...
Comparison of anti–PD-L1 with anti–PD-1 antibodies in the combination of HAIC and lenvatinib for the treatment of unresectable hepatocellular carcinoma. Prevalence of historical medical conditions or ...
A new review was published in Genes & Cancer on December 13, 2022, entitled, "Pathogenesis to management of hepatocellular carcinoma." In this review, researchers from multiple universities and ...
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the publication of Phase 1b data evaluating botensilimab (BOT), an Fc-enhanced anti-CTLA-4 antibody, in combination ...
Helio Genomics, an AI-powered TechBio company focused on early cancer detection, today announced the publication of a study in the Journal of Hepatology demonstrating the performance of HelioLiver™, ...
National Taiwan University Hospital (NTUH), in collaboration with multiple medical centers across Taiwan, has found that ...
Please provide your email address to receive an email when new articles are posted on . Survival for people with HCC has improved over the past decade. Much of the improvement has been limited to ...
Hepatocellular carcinoma (HCC) is the most common primary liver cancer and a leading cause of cancer-related deaths worldwide. While environmental and genetic factors contribute to HCC, increasing ...
Hepatocellular carcinoma (HCC) is the most common type of liver cancer. Most people who develop this cancer have chronic liver disease. Treatments typically include surgery, chemotherapy, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results